Enanta Pharmaceuticals (NASDAQ:ENTA) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report report published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $20.00 price target on the biotechnology company’s stock.

A number of other analysts have also commented on ENTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Enanta Pharmaceuticals Price Performance

ENTA opened at $12.18 on Thursday. The business has a 50 day simple moving average of $13.42 and a two-hundred day simple moving average of $12.64. The firm has a market capitalization of $353.46 million, a price-to-earnings ratio of -3.81 and a beta of 0.96. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The business had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Enanta Pharmaceuticals by 91.6% in the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after purchasing an additional 1,782,745 shares during the period. Commodore Capital LP purchased a new position in Enanta Pharmaceuticals during the third quarter valued at $9,576,000. Krensavage Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 30.8% during the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after buying an additional 651,946 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 30.6% during the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares in the last quarter. Finally, Millennium Management LLC grew its position in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.